CorMedix Statistics
Total Valuation
CorMedix has a market cap or net worth of $772.92 million. The enterprise value is $866.12 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CorMedix has 78.79 million shares outstanding. The number of shares has increased by 24.69% in one year.
| Current Share Class | 78.79M |
| Shares Outstanding | 78.79M |
| Shares Change (YoY) | +24.69% |
| Shares Change (QoQ) | +19.88% |
| Owned by Insiders (%) | 6.85% |
| Owned by Institutions (%) | 55.41% |
| Float | 73.39M |
Valuation Ratios
The trailing PE ratio is 4.36 and the forward PE ratio is 3.50.
| PE Ratio | 4.36 |
| Forward PE | 3.50 |
| PS Ratio | 3.10 |
| Forward PS | 1.55 |
| PB Ratio | 2.05 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 10.39 |
| P/OCF Ratio | 10.31 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.00, with an EV/FCF ratio of 11.64.
| EV / Earnings | 5.33 |
| EV / Sales | 4.04 |
| EV / EBITDA | 8.00 |
| EV / EBIT | 8.33 |
| EV / FCF | 11.64 |
Financial Position
The company has a current ratio of 1.94, with a Debt / Equity ratio of 0.40.
| Current Ratio | 1.94 |
| Quick Ratio | 1.60 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | 1.37 |
| Debt / FCF | 2.00 |
| Interest Coverage | 106.62 |
Financial Efficiency
Return on equity (ROE) is 75.08% and return on invested capital (ROIC) is 22.31%.
| Return on Equity (ROE) | 75.08% |
| Return on Assets (ROA) | 15.68% |
| Return on Invested Capital (ROIC) | 22.31% |
| Return on Capital Employed (ROCE) | 16.84% |
| Revenue Per Employee | $3.30M |
| Profits Per Employee | $2.50M |
| Employee Count | 65 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 0.69 |
Taxes
| Income Tax | -55.47M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.70% in the last 52 weeks. The beta is 1.31, so CorMedix's price volatility has been higher than the market average.
| Beta (5Y) | 1.31 |
| 52-Week Price Change | -1.70% |
| 50-Day Moving Average | 10.92 |
| 200-Day Moving Average | 11.15 |
| Relative Strength Index (RSI) | 39.79 |
| Average Volume (20 Days) | 3,132,077 |
Short Selling Information
The latest short interest is 17.45 million, so 22.14% of the outstanding shares have been sold short.
| Short Interest | 17.45M |
| Short Previous Month | 16.60M |
| Short % of Shares Out | 22.14% |
| Short % of Float | 23.77% |
| Short Ratio (days to cover) | 5.82 |
Income Statement
In the last 12 months, CorMedix had revenue of $214.30 million and earned $162.50 million in profits. Earnings per share was $2.25.
| Revenue | 214.30M |
| Gross Profit | 202.10M |
| Operating Income | 103.95M |
| Pretax Income | 107.03M |
| Net Income | 162.50M |
| EBITDA | 108.20M |
| EBIT | 103.95M |
| Earnings Per Share (EPS) | $2.25 |
Full Income StatementBalance Sheet
The company has $55.72 million in cash and $148.92 million in debt, giving a net cash position of -$93.20 million or -$1.18 per share.
| Cash & Cash Equivalents | 55.72M |
| Total Debt | 148.92M |
| Net Cash | -93.20M |
| Net Cash Per Share | -$1.18 |
| Equity (Book Value) | 374.13M |
| Book Value Per Share | 4.78 |
| Working Capital | 125.89M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $74.97 million and capital expenditures -$549,765, giving a free cash flow of $74.42 million.
| Operating Cash Flow | 74.97M |
| Capital Expenditures | -549,765 |
| Free Cash Flow | 74.42M |
| FCF Per Share | $0.94 |
Full Cash Flow StatementMargins
Gross margin is 94.31%, with operating and profit margins of 48.51% and 75.83%.
| Gross Margin | 94.31% |
| Operating Margin | 48.51% |
| Pretax Margin | 49.95% |
| Profit Margin | 75.83% |
| EBITDA Margin | 50.49% |
| EBIT Margin | 48.51% |
| FCF Margin | 34.73% |
Dividends & Yields
CorMedix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.69% |
| Shareholder Yield | -24.69% |
| Earnings Yield | 21.02% |
| FCF Yield | 9.63% |
Analyst Forecast
The average price target for CorMedix is $17.43, which is 77.68% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.43 |
| Price Target Difference | 77.68% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 53.41% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on March 26, 2019. It was a reverse split with a ratio of 1:5.
| Last Split Date | Mar 26, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
CorMedix has an Altman Z-Score of 1.74 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.74 |
| Piotroski F-Score | 5 |
